Cynata Therapeutics

1233 High Street
Suite 1
Armadale
Victoria
3143

Tel: 61-0-412-119343

Show jobs for this employer

38 articles with Cynata Therapeutics

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that it has entered into a new strategic partnership agreement with Fujifilm Corporation.

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by the Central Adelaide Local Health Network Human Research Ethics Committee to commence a clinical trial of Cynata’s Cymerus™ mesenchymal stem cell product in patients with diabetic foot ulcers.

  • Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement ( “Placement” ), led by a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate to invest in Australian based innovative healthcare techn

  • Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the Phase 3 SCUlpTOR (“Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis”) Trial of CYP-004, Cynata’s Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis, has now commenced.

  • Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced positive efficacy data from a study of its induced pluripotent stem cell -derived Cymerus™ mesenchymal stem cells in a preclinical rodent model of idiopathic pulmonary fibrosis.

  • Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.
  • Cynata Therapeutics Limited (ASX: CYP), a leading clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the MEND (MEseNchymal coviD-19) Trial is now open for patient enrolment. Following ethics committee approval (as announced on 8 May 2020), this important step represents the formal commencement of this clinical trial.

  • Cynata Therapeutics Limited (ASX: “ CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced positive results from the two-year follow-up of patients enrolled in the Phase 1 clinical trial of CYP-001, Cynata’s lead induced pluripotent stem cell (iPSC)-derived Cymerus™ mesenchymal stem cell (MSC) product. The Phase 1 trial, which was the world’s first clinical trial

  • Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to report important progress towards the commencement of recruitment in the Phase 3 clinical trial of CYP-004, its Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis

  • Cynata Therapeutics Limited (ASX: “ CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated gui

  • Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus™ mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). 1 The AJRCCM, commonly known as “ The Blue Journal

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received an additional A$618,667 R&D Tax Incentive Refund for the 2018/2019 financial year and to provide a market update on other activities.

  • Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 2 clinical trial of the Cymerus™ mesenchymal stem cell (MSC) product CYP-002 in patients with critical limb ischaemia (CLI).

  • Cynata Therapeutics Limited is pleased to announce data from a preclinical model demonstrating that its proprietary Cymerus™ mesenchymal stem cells (MSCs) significantly ameliorate the effects of cytokine release syndrome (CRS), a potentially severe and life-threatening adverse reaction to cancer immunotherapy.

  • Melbourne, Australia; 30 August 2018: Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that CYP-001, its lead Cymerus™ mesenchymal stem cell (MSC) product candidate, met all clinical endpoints in a Phase 1 trial for the treatment of steroid-resistant acute graft-versus-host disease (GvHD).

  • Cynata Therapeutics is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™.

  • Cynata is pleased to announce that the first stage of its ongoing study evaluating the ability to genetically engineer Cymerus mesenchymal stem cells for the potential treatment of certain cancers has been completed, with very promising results.

  • The first patient in Cohort B has been treated with CYP-001.

  • Cynata has entered into a MoU with Celularity, for the commercial evaluation of Cynata’s Cymerus production technology for use with Celularity's therapeutic stem cell technologies.